Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.
2026 · 1st Quarter (Jan 1 - Mar 31)
REGENERON PHARMACEUTICALS, INC
Filed by REGENERON PHARMACEUTICALS, INC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2026
- Income
- Not reported
- Expenses
- $640,000.00
- Registrant
- REGENERON PHARMACEUTICALS, INC
- Filing UUID
- 4ca44e7d-c920-430f-90c2-5a05a120f1c8
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.
Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers.
Trade and tariff issues related to corporations.
Tax and inflation issues related to corporations.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.